Handelsavisen
prelaunch
Companies Healthcare 311690.KQ
31
311690.KQ KOSDAQ Biotechnology & Medical Research

311690.Kq

$5 060,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
-671,2 %
ROE
-44,8 %
Net margin
-650,1 %
Debt / equity
0,19
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.

Business. The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-44,8 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 311690.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 311690.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 0.19, indicating a relatively low reliance on debt financing. However, the company's liquidity position is assessed as medium, with a current ratio of 3.6, suggesting it has sufficient short-term assets to cover its liabilities, but with some room for improvement. The company's valuation snapshot reveals a negative return on equity of -44.75% and a negative return on assets of -33.18%, indicating poor profitability and asset utilization.

    In terms of profitability, the company's operating income is significantly negative at -24.79 billion KRW, and its net income is also negative at -24.00 billion KRW, which is far below the industry median for profitability metrics. The company's gross profit of 698.91 million KRW is minimal compared to its total revenue of 3.69 billion KRW, suggesting high cost structures or low pricing power.

    The company's revenue is concentrated in a single segment, as disclosed in its financials, with no significant geographic diversification reported. This concentration may expose the company to higher risks if demand in its primary market fluctuates or if regulatory changes impact its operations.

    The company's growth trajectory is currently negative, with a significant decline in operating and net income. The outlook for the current fiscal year indicates a continuation of this trend, with no substantial improvement expected in the near term. The company's capital expenditure of -75.93 million KRW suggests minimal investment in new projects or expansion, which may limit its future growth potential.

    The company's risk assessment highlights a medium liquidity risk, primarily due to its negative operating and free cash flows, which are -23.42 billion KRW and -20.07 billion KRW, respectively. The dilution risk is assessed as low, with no significant dilution potential reported in the basic shares outstanding. The company's negative net cash position after subtracting total debt is a key flag that may impact its financial stability.

    Recent events, as disclosed in the company's financial filings, indicate ongoing challenges in achieving profitability and managing cash flows. The company has not reported any significant new product launches or strategic partnerships that could drive future growth. The lack of positive developments in recent filings suggests that the company may need to implement cost-cutting measures or seek additional financing to sustain operations.

    Key takeaways
    • The company has a negative return on equity and return on assets, indicating poor profitability and asset utilization.
    • The company's liquidity position is medium, with a current ratio of 3.6, suggesting it has sufficient short-term assets to cover its liabilities but with some room for improvement.
    • The company's revenue is concentrated in a single segment, which may expose it to higher risks if demand in its primary market fluctuates.
    • The company's growth trajectory is currently negative, with a significant decline in operating and net income, and no substantial improvement expected in the near term.
    • The company's risk assessment highlights a medium liquidity risk due to its negative operating and free cash flows.
    • **margin_outlook_rationale**: The company's gross margin is low, and the outlook for improvement is uncertain due to high cost structures and minimal gross profit.
    • **rd_outlook_rationale**: The company's research and development outlook is not explicitly provided, but the lack of significant new product launches suggests limited R&D investment.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $5 060,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $53.64B
    Net cash
    -$10.41B
    Current ratio
    3.6
    Debt / equity
    0.2
    ROA
    -33.2%
    ROE
    -44.8%
    Cash conversion
    98.0%
    CapEx / revenue
    -2.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-671,2 %Below median
    Net Margin-650,1 %Below median
    ROE-44,8 %Below median
    Capex / Rev-2,1 %Above median
    D/E0,19Below median
    Cash Conv0,98Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 311690.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    311690.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage